TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

NCT03964532

Last updated date
Study Location
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Contact
202-444-2223

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

202-444-2223

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed advanced breast cancer not amenable to curative treatment by surgery or radiotherapy, that is amenable to biopsy

- Radiographically measurable disease by RECIST v1.1

- Age ≥ 18 years

- Life expectancy of more than 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

- Signed informed consent form

- Adequate hepatic, bone marrow, and renal function as defined below in the body of the protocol

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior exposure to PARP inhibitor-based therapy


- Prior disease progression while receiving anti-PD-1 or anti-PD-L1 therapy within 6
months of use


- Recent severe infection or antibiotic use, or known chronic infection with human
immunodeficiency virus (HIV) or hepatitis B virus


- Diagnosis of immunodeficiency or is receiving systemic steroid or other
immunosuppressive therapy


- Active autoimmune disease that has required systemic treatment in the past 2 years


- History of tuberculosis


- History of allogenic bone marrow transplant or solid organ transplant


- Live vaccine administration within 30 days of planned start of study therapy


- Cardiovascular disease problems including unstable angina, therapy for lifethreatening
ventricular arrhythmia, or myocardial infarction, stroke within the last 6 months, or
a diagnosis of congestive heart failure


- Women who are pregnant or breastfeeding


- Patients with known untreated central nervous system (CNS) metastases


- Patients with history of another active malignancy within the past 2 years, excluding
non-melanoma carcinoma of the skin


- Patients receiving any other investigational agents

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast CancerCP-724,714 in Treating Patients With Metastatic Breast Cancer
NCT00055926
  1. Los Angeles, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast CancerPalbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
NCT04130152
  1. Barcelona,
  2. Barcelona,
  3. Madrid,
  4. Madrid,
  5. Malaga,
  6. Palma De Mallorca,
  7. Santiago De Compostela,
  8. Sevilla,
Female
18 Years+
years
MULTIPLE SITES
Breast CancerPErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
NCT02624973
  1. Lørenskog, Akershus
  2. Bergen, Hordaland
  3. Haugesund, Rogaland
  4. Stavanger, Rogaland
  5. Førde, Sogn Og Fjordande
  6. Trondheim, Sør Trøndelag
  7. Tromsø, Troms
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Official Title  ICMJE TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Brief Summary This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: Talazoparib
    Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
    Other Name: Talzenna
  • Drug: Avelumab
    Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
    Other Name: Bavencio
Study Arms  ICMJE Experimental: Phase I/Phase II
Talazoparib (1mg by mouth [PO] daily D1-28) will be provided as monotherapy for the first cycle. Starting with cycle 2 and for all subsequent cycles, treatment with avelumab (800 mg intravenously [IV] D1 every 2 weeks) will be added to talazoparib.
Interventions:
  • Drug: Talazoparib
  • Drug: Avelumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 24, 2019)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2021
Estimated Primary Completion Date December 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically confirmed advanced breast cancer not amenable to curative treatment by surgery or radiotherapy, that is amenable to biopsy
  • Radiographically measurable disease by RECIST v1.1
  • Age ? 18 years
  • Life expectancy of more than 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
  • Signed informed consent form
  • Adequate hepatic, bone marrow, and renal function as defined below in the body of the protocol

Exclusion Criteria:

  • Prior exposure to PARP inhibitor-based therapy
  • Prior disease progression while receiving anti-PD-1 or anti-PD-L1 therapy within 6 months of use
  • Recent severe infection or antibiotic use, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
  • Diagnosis of immunodeficiency or is receiving systemic steroid or other immunosuppressive therapy
  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • History of tuberculosis
  • History of allogenic bone marrow transplant or solid organ transplant
  • Live vaccine administration within 30 days of planned start of study therapy
  • Cardiovascular disease problems including unstable angina, therapy for lifethreatening ventricular arrhythmia, or myocardial infarction, stroke within the last 6 months, or a diagnosis of congestive heart failure
  • Women who are pregnant or breastfeeding
  • Patients with known untreated central nervous system (CNS) metastases
  • Patients with history of another active malignancy within the past 2 years, excluding non-melanoma carcinoma of the skin
  • Patients receiving any other investigational agents
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Filipa Lynce, MD202-444-2223[email protected]
Contact: Nellie Novielli, RN202-784-3923[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03964532
Other Study ID Numbers  ICMJE STUDY00000023
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Georgetown University
Study Sponsor  ICMJE Georgetown University
Collaborators  ICMJE Pfizer
Investigators  ICMJE Not Provided
PRS Account Georgetown University
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP